After an advisory panel of the U.S. Food and Drug Administration has voted not to recommend approval for a potential drug aimed at kidney cancer from AVEO Oncology , the company says it will work to address the issues cited with the trials.
http://www.bizjournals.com/boston/blog/bioflash/2013/05/fda-panel-rejects-aveos-kidney-cancer.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_32+%28Biotechnology+Industry+News%29
http://www.bizjournals.com/boston/blog/bioflash/2013/05/fda-panel-rejects-aveos-kidney-cancer.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_32+%28Biotechnology+Industry+News%29
No comments:
Post a Comment